Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Vera Therapeutics Inc Cl A
(NQ:
VERA
)
34.89
-1.00 (-2.79%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 24, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Vera Therapeutics Inc Cl A
< Previous
1
2
Next >
Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
March 28, 2023
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference
February 27, 2023
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Class A Common Stock
February 06, 2023
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock
February 01, 2023
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics Announces Commencement of Public Offering of Class A Common Stock
February 01, 2023
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics Releases 36 Week Interim Analysis of Phase 2b Clinical Trial of Atacicept for the Treatment of IgA Nephropathy; Patients in the 150 mg Dose Group Achieved a Delta of 48% Versus Placebo in Mean Reduction in Proteinuria
January 30, 2023
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics Hosting a Key Opinion Leader Webinar on Atacicept for the Treatment IgA Nephropathy (IgAN)
January 25, 2023
From
Vera Therapeutics
Via
GlobeNewswire
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Vera Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
January 12, 2023
From
The Schall Law Firm
Via
Business Wire
Vera Therapeutics Announces Positive Topline Results of Phase 2b ORIGIN Clinical Trial of Atacicept for the Treatment of IgA Nephropathy
January 03, 2023
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics to Participate in the 41st Annual J.P. Morgan Healthcare Conference
December 20, 2022
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics to Present at Upcoming Investor Conferences
November 22, 2022
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics to Host Key Opinion Webinar on Targeting the Source of IgA Nephropathy (IgAN) Featuring Jonathan Barratt, Ph.D., FRCP
November 17, 2022
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results
November 09, 2022
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics Presents New Analysis of Phase 2a JANUS Trial of Atacicept in IgA Nephropathy and Positive Final Phase 2 Results of MAU868 in Kidney Transplant Recipients with Reactivated BK Virus Infection at the American Society of Nephrology Kidney
November 05, 2022
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics to Present Final Phase 2 Results of MAU868 in Kidney Transplant Recipients with Reactivated BK Virus Infection and New Analysis of Phase 2a JANUS Trial of Atacicept in IgA Nephropathy at the American Society of Nephrology Kidney Week
October 17, 2022
From
Vera Therapeutics
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.